Virtual Mentor. July 2001, Volume 3, Number 7.
Cases in Law and Ethics
Is It Covered or Not? Health Plans and Experimental Procedures
An ethical case explores physicians' responsibility to provide quality care to their patients within the limitations of insurance reimbursements.
Kayhan Parsi, JD, PhD
Ms. Evans was diagnosed with stage II, node positive breast cancer. The primary tumor was 3 centimeters when diagnosed, and 14 of her 23 axillary lymph nodes were involved with the tumor. Ms. Evans underwent a lumpectomy, lymphadenectomy, and several months of standard-dose chemotherapy, all of which her health plan covered. Her physician, Dr. Bookman, discussed another possible follow-up treatment for her breast cancer. He believed that Ms. Evans' best chance for long-term survival required the administration of a procedure called high-dose chemotherapy/peripheral blood stem cell rescue (HDC/PBSCR). This is a three-step process. First, blood stem cells are harvested from the patient's circulating, or peripheral, blood and placed in temporary storage. Next, the patient undergoes a cycle of high dose chemotherapy in hopes of killing the cancer cells. After administration of the HDC, the stored blood stem cells, which also would have been attacked by the chemotherapy had they not been removed, are reinfused into the patient's bloodstream to relieve the toxic effects of the HDC.
Dr. Bookman requested that the health plan pre-approve payment of expenses for Ms. Evans' treatment. Part of the charge was for stem cell rescue procedure, but no CPT code existed for such a procedure. Moreover, the health plan determined that the HDC/PBSCR procedure was experimental and investigational in nature and should not be covered. This decision was made by a patient care committee composed of physicians employed by the health plan.
The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.
© 2001 American Medical Association. All Rights Reserved.